The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | CAR-T updates in myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some insights into recent updates in CAR-T therapy for the treatment of multiple myeloma. Prof. Raje first discusses how the approval of ciltacabtagene autoleucel (cilta-cel) has improved options for triple-class refractory and penta-refractory patients, and further explains the promise of idecabtagene vicleucel (ide-cel) and the importance of real-world data. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
